Patent · US Active

CDK2 inhibitors

US11970498B2 · kind B2 · utility

0Cited by
2References
26Claims
0Family size

Assignee

Inventors

Key dates

Filing dateFeb 8, 2023
Grant dateApr 30, 2024
Priority date
Expiry dateFeb 8, 2043

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07B2200/05
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present disclosure provides a compound represented by structural Formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.